
Recursion Pharma shares rise 4% after FDA aligns on Phase 3 trial for AI-driven drug REC-4881.
Recursion Pharmaceuticals' stock increased by 3.86% following FDA alignment on the Phase 3 trial design for its AI-enabled drug REC-4881 targeting familial adenomatous polyposis, a disease with no current approved treatments. The FDA accepted a prima...



